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The Comparative In Vitro Activity of FK-037 
(Cefoselis), a New Broad-spectrum Cephalosporin 
Anna King, Linda Bethune and Ian Phillips 
FK-037, a new parenteral cephalosporin, was active against clinical isolates of both gram-positive and gram-negative 
aerobic bacteria. The activity of FK-037 was similar to that of cefpirome and cefepime and generally superior to that of 
ceftazidime. Methicillin-resistant staphylococci were less susceptible than methicillin-sensitive isolates but most 
remained within the sensitive range. All streptococci and Enterobacteriaceae were sensitive as were the majority of 
isolates of Acinetobacter spp. and Pseudomonas aeruginosa. There was resistance amongst other non-fermentative 
gram-negative bacilli but this was species specific and most pseudomonads were sensitive, with resistance seen in 
Stenotrophomonas maltophilia, Alcaligenes spp. and Flavobacterium spp. 
FK-037 is a new parenteral oxime-type cephem which, 
like other P-lactam antibiotics, inhibits bacterial cell 
division by inactivation of enzymes involved in cell wall 
synthesis. Structural modifications of the cephem 
nucleus have produced a variety of cephalosporins 
which show increased stability to 6-lactamases and 
increased activity against gram-negative bacteria but 
somewhat decreased activity against gram-positive 
bacteria. Recent advances have produced agents such 
as cefpirome and cefepime with a much broader spec- 
trum of activity including gram-positive organisms (1). 
Preliminary studies (2, 3) and subsequent more detailed 
in vitro studies (4, 5) have shown that FK-037, which 
contains a 1-hydroxyethyl-5-amino pyrazoliomethyl 
moiety at  position three of the cephem ring, has good 
activity against streptococci and staphylococci, in- 
cluding methicillin-resistant isolates, and is stable to 
most p-lactamases. 
We have studied the in vitro activity of FK-037 
compared with that of cefepime, cefpirome, ceftazi- 
dime, meropenem, gentamicin and ciprofloxacin 
against clinical isolates of common gram-positive and 
gram-negative aerobic bacteria. 
Materials and Methods 
Organisms 
The strains inciuded in the study were all clinical 
isolates from St. Thomas’ Hospital and were selected to 
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include representative numbers of the different species, 
some of which were known to be resistant to many 
of the agents tested, including those with acquired 
aniinoglycoside and quinolone resistance, hyperpro- 
duction of chromosomal p-lactamases in Entero- 
bacteriaceae and pseudomonads and plasmid-mediated 
p-lactamases but no Enterobacteriaceae with extended 
spectrum p-lactamases were included since these do 
not occur in our patients. Isolates were identified by 
routine laboratory methods. 
Antimicrobial agents 
The agents tested, gifts of the manufacturers supplied 
as powders of known potency, were FK-037 (R.W. 
Johnson Pharmaceutical Research Institute), cefepime 
(Bristol Myers), cefpirome and gentamicin (Roussel 
Laboratories), ceftazidime (Glaxo), meropenem (Zenica) 
and ciprofloxacin (Bayer UK). 
Determination of minimum inhibitory concentrations (MICs) 
An agar dilution method was used and plates were 
inoculated with a 37-pin multipoint inoculator 
(Denley). The medium was Diagnostic Sensitivity Test 
agar (Oxoid CM261) supplemented with 5% saponin- 
lysed horse blood for the testing of streptococci. The 
bacteria were either grown in brain heart infusion 
broth (Oxoid CM266) or, in the case of streptococci, 
suspended in broth from fresh agar cultures and diluted 
to give a final inoculum of 104-105 CFU per spot. 
The plates were incubated overnight at  37°C in 
air (with 5% COz for Streptococcus przeurnoniae) or at  
35OC for staphylococci. Escherichia coli NCTC 10418 
(FK-037 MIC: 0.016 mg/l), Pseudornonar aeruginosa 
NCTC 10662 (FK-037 MIC: 2 mg/l) and Staphylo- 
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Table 1 In vitro activity against gram-positive cocci 
MIC (mg/ l )  
Organism (number tested) Compound  Range  Mlcso MIc9o 
Staphylococcus aureus 
methicillin-sensitive (32) 
Staphylococcus aureus 
methicillin-resistant (9) 
Staphylococcus saprophyticus 
(20) 
Coagulase-negative methicillin- 
sensitive staphylococci 
(30) 
Coagulase-negative methicillin- 
resistant staphylococci 
(16) 
Streptococcus pneumoniae 
(41) 
O-hemolytic streptococci 
Groups A, C & G (40) 
Streptococcus agalactiae (25) 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
ciprofloxacin 
0.5 - 4 
0.5 - 2 
0.25 - 2 
4 - 32 
0.06 - 0.5 
0.125 - 128 
0.125 - 2 
4 - 8  
2 - 8  
2 - 8  
16 - 32 
0.5 - 1 
0.25 - 128 
0.125 - 0.5 
0.5 - 1 
0.5 - 2 
0.25 - 1 
8 - 32 
0.06 - 0.5 
0.008 - 0.03 
0.25 - 0.5 
0.125 - 4 
0.125 - 4 
0.125 - 2 
4 - 64 
0.03 - 4 
0.016 - 32 
0.06 - 1 
0.25 - 16 
1 - 64 
0.5 - 64 
8 - >128 
0.06 - 32 
0.016 - 128 
0.25 - 8 
0.008 - 0.5 
0.016 - 1 
0.008 - 1 
0.06 - 8 
0.002 - 1 
0.5 - 8 
0.004 - 0.008 
0.008 - 0.03 
0.004 - 0.016 
0.03 - 0.25 
0.004 - 0.016 
0.25 - 4 
0.016 - 0.03 
0.06 - 0.125 
0.03 - 0.125 
0.25 - 0.5 
0.016 - 0.06 
0.5 - 2 
1 
0.5 
0.5 
8 
0.125 
0.25 
0.25 
4 
4 
2 
32 
1 
1 
0.5 
1 
2 
1 
16 
0.25 
0.016 
0.5 
0.5 
0.5 
0.25 
8 
0.125 
0.125 
0.25 
2 
2 
1 
32 
2 
8 
0.25 
0.016 
0.03 
0.03 
0.25 
0.008 
2 
0.008 
0.016 
0.008 
0.125 
0.008 
0.5 
0.03 
0.06 
0.06 
0.25 
0.06 
1 
2 
1 
1 
8 
0.125 
0.5 
1 
8 
8 
8 
32 
1 
128 
0.5 
1 
2 
1 
32 
0.25 
0.016 
0.5 
1 
2 
1 
16 
2 
16 
0.5 
8 
32 
16 
128 
16 
128 
0.5 
0.25 
1 
0.25 
8 
0.25 
4 
0.008 
0.03 
0.016 
0.25 
0.016 
1 
0.03 
0.125 
0.06 
0.25 
0.06 
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Table 2 In vitro activity against non-fastidious gram-negative bacilli 
MIC (mg/l) 
Organism (number tested) Compound Range MIC.50 MIC9o 
Escherichia coli (41) 
KIebsiella spp. (35) 
Citrobacter spp. (40) 
Acinetobacter spp. (37) FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
Pseudomonas aeruginosa (56) FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
Stenotrophomonas maltophilia FK-037 
(21) cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
Other non-fermenters* (46) FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
0.008 - 64 
0.03 - 64 
0.016 - 32 
0.06 - 16 
0.004 - 2 
0.06 - >128 
0.008 - >128 
0.5 - 32 
0.5 - 32 
0.5 - 32 
0.5 - 32 
0.06 - 16 
0.125 - >128 
0.06 - 128 
2 - 128 
0.5 - 64 
0.5 - 64 
1 - 128 
2 - >128 
2 - >128 
0.25 - 16 
0.125 - 128 
0.06 - 64 
0.125 - 128 
0.008 - 16 
0.25 - 128 
0.06 - >128 
0.008 - 8 
0.008 - 0.25 
0.016 - 0.5 
0.03 - 0.5 
0.008 - 8 
0.008 - 0.03 
0.25 - 128 
0.008 - 32 
0.004 - 0.25 
0.016 - 0.25 
0.016 - 0.5 
0.06 - 1 
0.25 - >I28 
0.016 - 0.06 
0.008 - 2 
0.016 - 0.5 
0.016 - 0.25 
0.016 - 0.5 
0.06 - 16 
0.016 - 0.06 
0.25 - 16 
0.002 - 0.25 
0.25 
0.5 
0.125 
1 
0.06 
0.5 
0.06 
2 
2 
2 
1 
0.5 
1 
0.25 
32 
8 
32 
8 
8 
32 
2 
2 
4 
8 
2 
0.5 
1 
0.125 
0.03 
0.06 
0.06 
0.125 
0.016 
1 
0.016 
0.03 
0.06 
0.03 
0.125 
0.03 
0.5 
0.03 
0.03 
0.03 
0.03 
0.25 
0.03 
0.5 
0.008 
16 
16 
32 
16 
0.5 
>128 
1 
8 
16 
16 
4 
4 
64 
8 
128 
32 
128 
32 
64 
>128 
4 
32 
32 
128 
8 
8 
>128 
2 
0.125 
0.125 
0.125 
0.5 
0.03 
4 
0.25 
0.125 
0.125 
0.25 
0.5 
0.03 
0.25 
0.25 
0.125 
0.25 
0.5 
0.03 
8 
0.03 
128 
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Table 2 (continued) 
MIC (mg/l) 
Organism (itumber tested) Compound Rarzge MIcso mic90 
Serratia spp. (25) FK-037 0.06 - 0.5 0.125 0.25 
cefepime 0.03 - 0.25 0.125 0.25 
cefpirome 0.03 - 0.25 0.06 0.125 
cefiazidime 0.06 - 0.5 0.125 0.25 
meropenem 0.03 - 0.06 0.03 0.06 
gentamicin 0.125 - 64 0.5 16 
ciprofloxacin 0.03 - 0.25 0.06 0.125 
Enferobarter spp. (62) 
Hafnia aluei (20) 
Proteus spp. (65) 
Protidencia spp. (74) 
FK-037 
cefepime 
cefpirome 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
FK-037 
cefepime 
cefpironie 
ceftazidime 
meropenem 
gentamicin 
ciprofloxacin 
0.016 - 8 0.06 
0.016 - 2 0.06 
0.016 - 4 0.06 
0.06 - 64 0.25 
0.008 - 0.25 0.03 
0.125 - 64 0.5 
0.008 - 32 0.016 
0.016 - 0.125 0.03 
0.016 - 0.06 0.03 
0.016 - 0.125 0.03 
0.25 - 4 1 
0.016 - 0.03 0.016 
0.25 - 1 0.5 
0.004 - 0.016 0.008 
FK-037 0.03 - 0.125 0.03 
cefepime 0.03 - 0.5 0.06 
ceftazidime 0.008 - 0.25 0.06 
meropenem 0.03 - 0.5 0.125 
ciprofloxacin 0.004 - 0.5 0.03 
cefpirome 0.06 - 0.5 0.125 
gentamicin 0.06 - 16 1 
FK-037 0.004 - 8 0.06 
cefepime 0.008 - 1 0.06 
cefpirome 0.008 - 4 0.125 
cefiazidime 0.008 - 4 0.25 
meropenem 0.016 - 0.25 0.06 
gentamicin 0.125 - >128 2 
ciprofloxacin 0.004 - 2 0.06 
0.25 
0.25 
0.25 
2 
0.125 
8 
0.06 
0.06 
0.06 
0.06 
2 
0.03 
1 
0.016 
0.06 
0.125 
0.25 
0.125 
0.25 
4 
0.06 
0.5 
0.125 
0.5 
1 
0.125 
64 
1 
FK-037 0.016 - 0.125 0.03 0.06 
cefepime 0.016 - 0.25 0.03 0.06 
cefpirome 0.016 - 0.25 0.03 0.06 
ceftazidime 0.03 - 4 0.125 1 
meropenem 0.03 - 0.125 0.06 0.125 
gentamicin 0.25 - 128 0.5 8 
ciprofloxacin 0.008 - 8 0.016 0.06 
*Alaligenes spp. (4 isolates), Comamonar acidovorans (1 I), Flavobacterium spp. (2), Burkholderia cepacia (2), Pseudomonarjuorescens (10) Pseudomonas 
putida (lo), Pseudornonas stuutzeri (4), and one isolate each of Achromobacter xylosoxidans, Agrobacterium radiobacter and Ochrobacmm anthropi 
COCCUS aureus NCTC 6571 (FK-037 MIC: 0.5 mg/l) to that of cefpirome and cefepime, the two other fourth 
were included as control strains. generation cephalosporins tested, and superior to that 
of ceftazidime against all staphylococci at  35"C, the 
Results and discussion temperature used for testing. Methicillin-sensitive 
staphylococci were more sensitive to all the p-lactam 
Comparative MICs against gram-positive bacteria are antibiotics than were methicillin-resistant strains. How- 
shown in Table l. The activity of FK-037 was similar ever, when a breakpoint of 8 mg/l was employed for 
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FK-037, the majority of staphylococci fell within 
the sensitive range as for cefepime and cefpirome 
but it remains to be proven to be effective in vivo. 
The majority of Staphylococcus aureus isolates were also 
sensitive in vitro to meropenem but many methicillin- 
resistant coagulase-negative staphylococci were resis- 
tant. Ceftazidime was 4 to 8-fold less active than 
FK-037 against methicillin-sensitive staphylococci 
and all methicillin-resistant isolates were resistant to 
ceftazidime. 
FK-037, like cefepime, cefpirome and meropenem, 
was highly active against Streptococcus pneumoniae. 
Although penicillin-resistant isolates (penicillin MICs: 
0.25-2 mg/l) were less sensitive they were still well 
within the conventional sensitive range (FK437 MICs: 
0.06-0.5 mg/l): there was an excellent correlation 
of MICs of the two compounds ( ~ 0 . 9 5 ) .  All the P- 
lactams were active against P-haemolytic streptococci 
but ceftazidime was the least active of these agents, as 
it was for most gram-positive bacteria. 
Comparative activity against non-fastidious gram- 
negative bacilli is shown in Table 2. The activity of all 
the cephalosporins was similar against Acinetobacter spp., 
which were not further identified, and they were less 
active than meropenem, the only agent to which none 
of the isolates were resistant. All the p-lactams were 
active against most isolates of Pseudomonas aeruginosa but 
none of them had good activity against Stenotropho- 
monas maltophilia. There were isolates resistant to 
FK-037 amongst the other non-fermentative gram- 
negative aerobes as there were to all the agents tested 
but resistance to the p-lactams was generally species- 
specific. All the pseudomonads tested were sensitive to 
FK-037 (MICs: 0.5-8 mg/l for PseudomonasJuorescens, 
Pseudomonas putida and Burkholderia cepacia and 
0.125-0.25 mg/l for Pseudomonas stutzer9 as were half 
the isolates of Cornamonas acidovorans and the one isolate 
of Agrobacterium radiobacter but the remainder of 
the isolates, including all the Alcaligenes spp., both 
Flavobacterium spp. and the single isolates of Ochro- 
bactrum anthropi and Achromobacter xylosoxidans were 
resistant (FK-037 MICs: 16-128 mg/l). The range of 
activity of cefpirome and cefepime was similar to that 
of FK-037 against these isolates but ceftazidime was 
more active and all the Comamonas acidovorans and 
Alcaligenes spp. were sensitive. Both isolates of Flavo- 
bacterium spp. were resistant to meropenem and all other 
species were sensitive, though meropenem MICs for 
Pseudomonas Juorescens and Pseudomonas putida were 
close to the breakpoint. 
FK-037, like cefpirome and cefepime, was highly 
active against Enterobacteriaceae including strains 
known to produce plasmid-mediated and chromosomal 
p-lactamases. The one exception was a strain of 
Enterobacter cloacae with derepressed chromosomal 
P-lactamase which was resistant to ceftazidime (MIC: 
64 mg/l) and also had decreased sensitivity to FK-037 
(MIC: 8 mg/l) and to cefpirome and cefepime (MIC: 
4 mg/l). There was little difference between the three 
agents except against Proteus spp. and Providencia spp. for 
which cefpirome was the least active and FK-037 the 
most active of these three. There was one isolate of 
Providencia stuartii with decreased sensitivity to FK-037 
(MIC: 8 mg/l) and to cefpirome (MIC: 4 mg/l) but 
this isolate was more sensitive to ceftazidime and 
cefepime (MIC for both agents: 1 mg/l). 
There was no evidence of cross-resistance between 
FK-037 and gentamicin or ciprofloxacin against either 
gram-positive or gram-negative bacteria although a few 
multi-resistant isolates were amongst the least sensitive 
to FK-037 and the other cephalosporins. 
Our results have shown, like those of other 
workers (4, 5) that FK-037 is a promising new stable 
broad spectrum cephalosporin, that, like cefpirome and 
cefepime, it is more active in vitro than ceftazidime 
against most isolates, and that there appears to be little 
or no effect on FK-037 by the commonly encountered 
p-lactamases. If pharmacological and animal studies 
indicate, assessment for clinical use is warranted. 
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